The role of pharmacies in implementing modern protocols for the pharmacotherapy of type 2 diabetes mellitus
DOI:
https://doi.org/10.24959/sphhcj.25.357Keywords:
pharmacy; Ukrainian Clinical Protocol; international guidelines; pharmacotherapy; type 2 diabetes; hypoglycemic drugs.Abstract
The incidence of diabetes in different countries ranges from 1.5 to 10% and only about 50% of patients with type 2 diabetes achieve glycemic control. Therefore, studying factors that contribute to improving disease control and preventing complications is relevant.
The aim is to study the capabilities of a pharmacy in implementing modern guidelines for pharmacotherapy of type 2 diabetes based on an analysis of the assortment and sales of the hypoglycemic drugs over a 3-month period.
Materials and methods: assortment of hypoglycemic drugs in a pharmacy, sales report of various pharmacological groups of hypoglycemic drugs and fixed-dose combination drug. Analytical and statistical methods were used in the research.
Results. Analysis of the assortment of hypoglycemic drugs in the pharmacy showed the presence of five out of six pharmacological classes recommended by modern guidelines: Biguanides, Inhibitors of sodium-dependent glucose cotransporter type 2, Antagonists of glucagon-like peptide type 1 receptors, Dipeptidyl peptidase 4 inhibitors and Sulfonylureas. Thiazolidinediones are absent in the pharmacy. This range of hypohlygemic drugs corresponds the international guidelines and the Unified Ukrainian Clinical Protocol for Medical Care for Type 2 Diabetes. Analysis of sales of hypoglycemic drugs in the pharmacy showed that the leading positions in sales are occupied by Biguanides and Sulfonylureas. Combined hypoglycemic drugs in the pharmacy are represented by combinations of Biguanides with Sulfonylureas, with Dipeptidyl peptidase 4 inhibitors and Inhibitors of sodium-dependent glucose cotransporter type 2. But sales of combined diabetes-lowering drugs in pharmacies account for only 28.34%, with 40.3% of them being sales of the combination of Metformin and Glibenclamide.
Conclusions. The results of the research showed that modern guidelines for pharmacotherapy of type 2 diabetes are partially implemented in pharmacies, but at the same time, patients' access to drugs that allow for effective control of glycemia is ensured. The key negative trends are the low percentage of sales of drugs for the prevention of complications of diabetes and fixed-dose combination drug. To improve the practical implementation of guidelines, it is necessary to pay more attention to the study of dynamic changes in international guidelines and the Ukrainian Clinical Protocol For Medical Care For Type 2 Diabetes during the continuous professional development of pharmacy specialists.
References
Епідеміологія цукрового діабету в Україні. Здоров’я України | Інформація для спеціалістів охорони здоров’я - Health-ua. URL: https://health-ua.com/article/18197-epdemologya-tcukrovogo-dabetu-v-ukran.
Ukrinform. В Україні 1,2 мільйона людей з цукровим діабетом, реальна кількість може бути більшою - Ляшко. Укрінформ - актуальні новини України та світу. URL: https://www.ukrinform.ua/rubric-society/3927019-v-ukraini-12-miljona-ludej-z-cukrovim-diabetom-realna-kilkist-moze-buti-bilsou-lasko.html#:~:text=.
У пів мільйона українців діагностовано цукровий діабет у 2023 році. Міністерство охорони здоров’я України. URL: https://moz.gov.ua/uk/u-piv-miljona-ukrainciv-diagnostovano-cukrovij-diabet-u-2023-roci.
Diabetes. World Health Organization (WHO). URL: https://www.who.int/news-room/fact-sheets/detail/diabetes.
IDF Diabetes Atlas 2025. Diabetes Atlas. URL: https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/.
Уніфікований клінічний протокол первинної та спеціалізованої медичної допомоги «Цукровий діабет 2 типу у дорослих». Державний експертний центр Міністерства охорони здоров’я України. URL: https://www.dec.gov.ua/wp-content/uploads/2024/07/1300_24072024_ykpmd_diabet_2.pdf.
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) / M. J. Davies et al. Diabetes Care. 2022. URL: https://doi.org/10.2337/dci22-0034.
Recommendations | Type 2 diabetes in adults: management | Guidance | NICE. Homepage | NICE. URL: https://www.nice.org.uk/guidance/ng28/chapter/Recommendations.
Standards of Medical Care in Diabetes–2020 Abridged for Primary Care Providers. Clinical Diabetes. 2019. Vol. 38, no. 1. P. 10–38. URL: https://doi.org/10.2337/cd20-as01.
Drug Therapies for Diabetes / R. Weinberg Sibony et al. International Journal of Molecular Sciences. 2023. Vol. 24, no. 24. P. 17147. URL: https://doi.org/10.3390/ijms242417147.
Богуславський, Є. П., Воскобойнікова, Г. Л., & Гой, А. М. . Аналіз тенденцій позиціонування фармацевтичних препаратів класу SGLT -2 похідних гліфлозину на фармацевтичному ринку і перспектив застосування. Соціальна фармація в охороні здоров’я, 2023. Т.9. № 1. Р. 72-83. https://doi.org/10.24959/sphhcj.23.282
RACGP - The Royal Australian College of General Practitioners. URL: https://www.racgp.org.au/getattachment/010e971d-81a6-435e-90d0-8bb15eff8f7e/Management-of-type-2-diabetes-A-handbook-for-general-practice-Clinical-summary.pdf.aspx.
Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review / X. Xie et al. Frontiers in Endocrinology. 2023. Vol. 14. URL: https://doi.org/10.3389/fendo.2023.1301093.
Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel / S. Kalra et al. Journal of Family Medicine and Primary Care. 2020. Vol. 9, no. 11. P. 5450. URL: https://doi.org/10.4103/jfmpc.jfmpc_843_20
The availability of essential medicines for diabetes at health facilities in Bangladesh: evidence from 2014 and 2017 national surveys / S. Hakim et al. BMC Health Services Research. 2022. Vol. 22, no. 1. URL: https://doi.org/10.1186/s12913-022-07738-4 .
Access to essential medicines for diabetes care: availability, price, and affordability in central Ethiopia / H. D. Deressa et al. Global Health Research and Policy. 2024. Vol. 9, no. 1. URL: https://doi.org/10.1186/s41256-024-00352-3.
Analysis of fixed dose combinations and price variations of oral antidiabetic agents in the Indian pharmaceutical market / A. D. Geetha et al. Indian Journal of Pharmacy and Pharmacology. 2024. Vol. 11, no. 4. P. 213–220. URL: https://doi.org/10.18231/j.ijpp.2024.035.
Economic Effects of Fixed-Dose Versus Loose-Dose Combination Therapy for Type 2 Diabetes Patients / A. K. Böhm et al. Appl Health Econ Health Policy. 2023. no. 21. Р. 109–118 URL: https://doi.org/10.1007/s40258-022-00760-x.
Vlasenko I. O., Davtian L. L., Zaliska O. M. Вивчення фармацевтичного забезпечення терапії цукрового діабету 2 типу в Україні. Фармацевтичний часопис. 2022. № 2. С. 12–20. URL: https://doi.org/10.11603/2312-0967.2022.2.13332.
Vlasenko I. O. Вивчення преференцій лікарів для оптимізації аптечного асортименту цукрознижувальних препаратів. Фармацевтичний журнал. 2023. Т.78. № 3. Р. 18-29. URL: https://doi.org/10.32352/0367-3057.3.23.02
Власенко, І. О., Кубарєва, І. В., Давтян, Л. Л., & Корж, Ю. В.. Дослідження сучасних аспектів визначення вартості самоконтролю цукрового діабету. Соціальна фармація в охороні здоров’я. 2022. Т.8. № 2. Р. 19–27. URL: https://doi.org/10.24959/sphhcj.22.259
Ліки Контроль. URL: https://likicontrol.com.ua/.
Наказ МОЗ України від 13.03.2025 № 440 "Про затвердження Переліків лікарських засобів і медичних виробів, які підлягають реімбурсації за програмою державних гарантій медичного обслуговування населення, станом на 26 лютого 2025 року" Міністерство охорони здоровʼя URL: https://moz.gov.ua/uk/decrees/nakaz-moz-ukrayini-vid-13-03-2025-440-pro-zatverdzhennya-perelikiv-likarskih-zasobiv-i-medichnih-virobiv-yaki-pidlyagayut-reimbursaciyi-za-programoyu-derzhavnih-garantij-medichnogo-obslugovuvannya-naselennya-stanom-na-26-lyutogo-2025-roku
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
